Poor prognosis in acute lymphoblastic leukemia may relate to promoter hypermethylation of cancer-related genes

References

• Laird P W. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003; 3: 253–266
   PubMed Web of Science ®Google Scholar
• Clark S J, Harrison J, Paul C L, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res 1994; 22: 2990–2997
   PubMed Web of Science ®Google Scholar
• Herman J G, Graff J R, Myohanen S, Nelkin B D, Baylin S B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821–9826
   PubMed Web of Science ®Google Scholar
• Ahuja N, Issa J P. Aging, methylation and cancer. Histol Histopathol 2000; 15: 835–842
   PubMed Web of Science ®Google Scholar
• Cravo M L, Pinto A G, Chaves P, Cruz J A, Lage P, Nobre L C, et al. Effect of folate supplementation on DNA methylation of rectal mucosa in patients with colonic adenomas: correlation with nutrient intake. Clin Nutr 1998; 17: 45–49
   PubMed Web of Science ®Google Scholar
• James S J, Pogribny I P, Pogribna M, Miller B J, Jernigan S, Melnyk S. Mechanisms of DNA damage, DNA hypomethylation, and tumor progression in the folate/methyl-deficient rat model of hepatocarcinogenesis. J Nutr 2003; 133: 3740S–3747S
   PubMed Web of Science ®Google Scholar
• Pufulete M, Emery P W, Sanders T A. Folate, DNA methylation and colo-rectal cancer. Proc Nutr Soc 2003; 62: 437–445
   PubMed Web of Science ®Google Scholar
• Fang J Y, Xiao S D. Folic acid, polymorphism of methyl-group metabolism genes, and DNA methylation in relation to GI carcinogenesis. J Gastroenterol 2003; 38: 821–829
   PubMed Web of Science ®Google Scholar
• Matsuo K, Hamajima N, Suzuki R, Ogura M, Kagami Y, Taji H, et al. Methylenetetrahydrofolate reductase gene (MTHFR) polymorphisms and reduced risk of malignant lymphoma. Am J Hematol 2004; 77: 351–357
   PubMed Web of Science ®Google Scholar
• Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002; 21: 5427–5440
   PubMed Web of Science ®Google Scholar
• Pui C-H, Evans W E. Acute lymphoblastic leukemia. N Engl J Med 1998; 339: 605–615
   PubMed Web of Science ®Google Scholar
• Pui C-H, Behm F G, Crist W M. Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 1993; 82: 343–362
   PubMed Web of Science ®Google Scholar
• Ponder B AJ. Cancer genetics. Nature 2001; 411: 336–341
   PubMed Web of Science ®Google Scholar
• Pui C -H, Crist W M, Look A T. Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood 1990; 76: 1449–1463
   PubMed Web of Science ®Google Scholar
• Faderl S, Kantarjian H M, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 1998; 91: 3995–4019
   PubMed Web of Science ®Google Scholar
• Wada M, Bartram C R, Nakamura H, Hachiya M, Chen D L, Borenstein J, et al. Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood 1993; 82: 3163–3169
   PubMed Web of Science ®Google Scholar
• Jones P A, Laird P W. Cancer epigenetics comes of age. Nature Genet 1999; 21: 163–167
   PubMed Web of Science ®Google Scholar
• Wolffe A P, Matzke M A. Epigenetics: regulation through repression. Science 1999; 286: 481–486
   PubMed Web of Science ®Google Scholar
• Tycko B. Epigenetic gene silencing in cancer. J Clin Invest 2000; 105: 401–407
   PubMed Web of Science ®Google Scholar
• Herman J G, Baylin S B. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042–2054
   PubMed Web of Science ®Google Scholar
• Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003; 33: 245–254
   PubMed Web of Science ®Google Scholar
• Feinberg A P, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004; 4: 143–153
   PubMed Web of Science ®Google Scholar
• Singal R, Ginder G D. DNA methylation. Blood 1999; 93: 4059–4070
   PubMed Web of Science ®Google Scholar
• Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 1998; 12: 599–606
   PubMed Web of Science ®Google Scholar
• Nan X, Ng H H, Johnson C A, Laherty C D, Turner B M, Eisenman R N, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998; 393: 386–389
   PubMed Web of Science ®Google Scholar
• Jones P L, Veenstra G J, Wade P A, Vermaak D, Kass K U, Landsberger N, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998; 19: 187–191
   PubMed Web of Science ®Google Scholar
• Mannervik M, Nibu Y, Zhang H, Levine M. Transcriptional coregulators in development. Science 1999; 284: 606–609
   PubMed Web of Science ®Google Scholar
• Hendrich B, Bird A. Mammalian methyltransferases and methyl-CpG binding domains: proteins involved in DNA methylation. Curr Top Microbiol Immunol 2000; 249: 55–74
   PubMed Web of Science ®Google Scholar
• Rountree M R, Bachman K E, Herman J G, Baylin S B. DNA methylation, chromatin inheritance, and cancer. Oncogene 2001; 20: 3156–3165
   PubMed Web of Science ®Google Scholar
• Im H, Grass J A, Christensen H M, Perkins A, Bresnick E H. Histone deacetylase-dependent establishment and maintenance of broad low-level histone acetylation within a tissue-specific chromatin domain. Biochemistry 2002; 41: 15152–15160
   PubMed Web of Science ®Google Scholar
• El Osta A. DNMT cooperativity – the developing links between methylation, chromatin structure and cancer. Bioessays 2003; 25: 1071–1084
   PubMed Web of Science ®Google Scholar
• Pietenpol J A, Bohlander S K, Sato Y, Papadopoulus N, Liu B, Friedman C, et al. Assignment of the human p27kip1 gene to 12p13 and its analysis in leukemias. Cancer Res 1995; 55: 1206–1210
   PubMed Web of Science ®Google Scholar
• Hsieh C L. Dependence of transcriptional repression on CpG methylation density. Mol Cell Biol 1994; 14: 5487–5494
   PubMed Web of Science ®Google Scholar
• Vertino P M, Yen R W, Grao J, Baylin S B. De novo methylation of CpG island sequences in human fibroblasts overexpressing DNA (cytosine-5)-methyltransferase. Mol Cell Biol 1996; 16: 4555–4565
   PubMed Web of Science ®Google Scholar
• Graff J R, Herman J G, Myohanen S, Baylin S B, Vertino P M. Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. J Biol Chem 1997; 272: 22322–22329
   PubMed Web of Science ®Google Scholar
• Myohanen S K, Baylin S B, Herman J G. Hypermethylation can selectively silence individual p16ink4a alleles in neoplasia. Cancer Res 1998; 58: 591–593
   PubMed Web of Science ®Google Scholar
• Esteller M, Corn P G, Baylin S B, Herman J G. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61: 3225–3229
   PubMed Web of Science ®Google Scholar
• Costello J F, Fruhwald M C, Smiraglia D J, Rush L J, Robertson G P, Gao X, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000; 24: 132–138
   PubMed Web of Science ®Google Scholar
• Sakashita K, Koike K, Kinoshita T, Shiohara M, Kamijo T, Taniguchi S, et al. Dynamic DNA methylation change in the CpG island region of p15 during human myeloid development. J Clin Invest 2001; 108: 1195–1204
   PubMed Web of Science ®Google Scholar
• Roman-Gomez J, Castillejo J A, Jimenez A, Gonzalez M G, Moreno F, Rodriguez M C, et al. 5′ CpG island hypermethylation is associated with transcriptional silencing of the p21CIP1/WAF1/SDI1gene and confers poor prognosis in acute lymphoblastic leukemia. Blood 2002; 99: 2291–2296
   PubMed Web of Science ®Google Scholar
• Agirre X, Vizmanos J L, Calazans M J, Garcia-Delgado M, Larrayoz M J, Novo F J. Methylation of CpG dinucleotides and/or CCWGG motifs at the promoter of TP53 correlates with decreased gene expression in a subset of acute lymphoblastic leukemia patients. Oncogene 2003; 22: 1070–1072
   PubMed Web of Science ®Google Scholar
• Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo J A, Barrios M, Andreu E J, et al. The normal epithelial cell-specific 1 (NES1) gene, a candidate tumor suppressor gene on chromosome 19q13.3 – 4, is downregulated by hypermethylation in acute lymphoblastic leukemia. Leukemia 2004; 18: 362–365
   PubMed Web of Science ®Google Scholar
• Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo J A, Navarro G, Barrios M, et al. Transcriptional silencing of the Dickkopfs-3 (Dkk-3) gene by CpG hypermethylation in acute lymphoblastic leukaemia. Br J Cancer 2004; 91: 707–713
   PubMed Web of Science ®Google Scholar
• Jimenez-Velasco A, Roman-Gomez J, Agirre X, Barrios M, Navarro G, Vazquez I, et al. Downregulation of the large tumor suppressor 2 (LATS2 / KPM) gene confers poor prognosis in acute lymphoblastic leukemia. Leukemia 2005; 19: 2347–2350
   PubMed Web of Science ®Google Scholar
• Agirre X, Roman-Gomez J, Vazquez I, Jimenez-Velasco A, Garate L, Montiel-Duarte C, et al. Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia (CML). Int J Cancer 2006; 118: 1945–1953
   PubMed Web of Science ®Google Scholar
• Agirre X, Roman-Gomez J, Jimenez-Velasco A, Garate L, Montiel-Duarte C, Navarro G, et al. ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia. Oncogene 2006; 25: 1862–1870
   PubMed Web of Science ®Google Scholar
• San Jose-Eneriz E, Agirre X, Roman-Gomez J, Cordeu L, Garate L, Jimenez-Velasco A, et al. Downregulation of DBC1 expression in acute lymphoblastic leukaemia is mediated by aberrant methylation of its promoter. Br J Haematol 2006; 134: 137–144
   PubMed Web of Science ®Google Scholar
• Shen L, Toyota M, Kondo Y, Obata T, Daniel S, Pierce S, et al. Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood 2003; 101: 4131–4136
   PubMed Web of Science ®Google Scholar
• Roman-Gomez J, Jimenez-Velasco A, Castillejo J A, Agirre X, Barrios M, Navarro G, et al. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood 2004; 104: 2492–2498
   PubMed Web of Science ®Google Scholar
• Roman-Gomez J, Jimenez-Velasco A, Agirre X, Prosper F, Heiniger A, Torres A. Lack of CpG island methylator phenotype defines a clinical subtype of T-cell acute lymphoblastic leukemia associated with good prognosis. J Clin Oncol 2005; 23: 7043–7049
   PubMed Web of Science ®Google Scholar
• Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo J A, Navarro G, Calasanz M J, et al. CpG island methylator phenotype redefines the prognostic effect of t(12;21) in childhood acute lymphoblastic leukemia. Clin Cancer Res 2006; 12: 4845–4850
   PubMed Web of Science ®Google Scholar
• Roman-Gomez J, Cordeu L, Agirre X, Jimenez-Velasco A, San Jose-Eneriz E, Garate L, et al. Epigenetic regulation of WNT signaling pathway in acute lymphoblastic leukemia. Blood 2007; 109: 3462–3469
   PubMed Web of Science ®Google Scholar
• Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo J A, Navarro G, Garate L, et al. Promoter hypermethylation and global hypomethylation are independent epigenetic events in lymphoid leukemogenesis with opposing effects on clinical outcome. Leukemia 2006; 20: 1445–1448
   PubMed Web of Science ®Google Scholar
• Roman-Gomez J, Castillejo J A, Jimenez A, Gonzalez M G, Reina M L, Rodriguez M C, et al. Hypermethylation of the calcitonin gene in acute lymphoblastic leukemia is associated with unfavourable clinical outcome. Br J Haematol 2001; 113: 329–338
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Daniel I, Smith T L, Kornblau S M, Kantarjian H M, Issa J-P. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res 2002; 8: 2217–2224
   PubMed Web of Science ®Google Scholar
• Gutierrez M I, Siraj A K, Bhargava M, Ozbek U, Banavali S, Chaudhary M A, et al. Concurrent methylation of multiple genes in childhood ALL: correlation with phenotype and molecular subgroup. Leukemia 2003; 17: 1845–1850
   PubMed Web of Science ®Google Scholar
• Takahashi T, Shivapurkar N, Reddy J, Shigematsu H, Miyajima K, Suzuki M, et al. DNA methylation profiles of lymphoid and hematopoietic malignancies. Clin Cancer Res 2004; 10: 2928–2935
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Bueso-Ramos C, Daniel J, Williamson J, Kantarjian H M, Issa J P. DNA methylation patterns at relapse in adult acute lymphocytic leukemia. Clin Cancer Res 2002; 8: 1897–1903
   PubMed Web of Science ®Google Scholar
• Matsushita C, Yang Y, Takeuchi S, Matsushita M, van Dongen J J, Szczepanski T, et al. Aberrant methylation in promoter-associated CpG islands of multiple genes in relapsed childhood acute lymphoblastic leukemia. Oncol Rep 2004; 12: 97–99
   PubMed Web of Science ®Google Scholar
• Uehara E, Takeuchi S, Tasaka T, Matsuhashi Y, Yang Y, Fujita M, et al. Aberrant methylation in promoter-associated CpG islands of multiple genes in therapy-related leukemia. Int J Oncol 2003; 23: 693–696
   PubMed Web of Science ®Google Scholar
• Ren Y, Roy S, Ding Y, Iqbal J, Broome J D. Methylation of the asparagine synthetase promoter in human leukemic cell lines is associated with a specific methyl binding protein. Oncogene 2004; 23: 3953–3961
   PubMed Web of Science ®Google Scholar
• Roman-Gomez J, Castillejo J A, Jimenez A, Barrios M, Heiniger A, Torres A. The role of DNA hypermethylation in the pathogenesis and prognosis of acute lymphoblastic leukemia. Leuk Lymphoma 2003; 44: 1855–1864
   PubMed Web of Science ®Google Scholar
• Scholz C, Nimmrich I, Burger M, Becker E, Dorken B, Ludwig W D, et al. Distinction of acute lymphoblastic leukemia from acute myeloid leukemia through microarray-based DNA methylation analysis. Ann Hematol 2005; 84: 236–244
   PubMed Web of Science ®Google Scholar
• Gemmati D, Ongaro A, Scapoli G L, Della P M, Tognazzo S, Serino M L, et al. Common gene polymorphisms in the metabolic folate and methylation pathway and the risk of acute lymphoblastic leukemia and non-Hodgkin's lymphoma in adults. Cancer Epidemiol Biomarkers Prev 2004; 13: 787–794
   PubMed Web of Science ®Google Scholar
• Moore L E, Huang W Y, Chung J, Hayes R B. Epidemiologic considerations to assess altered DNA methylation from environmental exposures in cancer. Ann N Y Acad Sci 2003; 983: 181–196
   PubMed Web of Science ®Google Scholar
• Shivapurkar N, Takahashi T, Reddy J, Zheng Y, Stastny V, Collins R, et al. Presence of simian virus 40 DNA sequences in human lymphoid and hematopoietic malignancies and their relationship to aberrant promoter methylation of multiple genes. Cancer Res 2004; 64: 3757–3760
   PubMed Web of Science ®Google Scholar
• Oka T, Ouchida M, Koyama M, Ogama Y, Takada S, Nakatani Y, et al. Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res 2002; 62: 6390–6394
   PubMed Web of Science ®Google Scholar
• Goodman P A, Burkhardt N, Juran B, Tibbles H E, Uckun F M. Hypermethylation of the spleen tyrosine kinase promoter in T-lineage acute lymphoblastic leukemia. Oncogene 2003; 22: 2504–2514
   PubMed Web of Science ®Google Scholar
• Ponder B AJ. Cancer genetics. Nature 2001; 411: 336–341
   PubMed Web of Science ®Google Scholar
• Wada M, Bartram C R, Nakamura H, Hachiya M, Chen D L, Borenstein J, et al. Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood 1993; 82: 3163–3169
   PubMed Web of Science ®Google Scholar
• Plasschaert S L, Kamps W A, Vellenga E, de Vries E G, de Bont E S. Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation?. Cancer Treat Rev 2004; 30: 37–51
   PubMed Web of Science ®Google Scholar
• Yasunaga J, Taniguchi Y, Nosaka K, Yoshida M, Satou Y, Sakai T, et al. Identification of aberrantly methylated genes in association with adult T-cell leukemia. Cancer Res 2004; 64: 6002–6009
   PubMed Web of Science ®Google Scholar
• Nakatsuka S, Takakuwa T, Tomita Y, Hoshida Y, Nishiu M, Yamaguchi M, et al. Hypermethylation of death-associated protein (DAP) kinase CpG island is frequent not only in B-cell but also in T- and natural killer (NK)/T-cell malignancies. Cancer Sci 2003; 94: 87–91
   PubMed Web of Science ®Google Scholar
• Yang Y, Takeuchi S, TsukasakI K, Yamada Y, Hata T, Mori N, et al. Methylation analysis of the adenomatous polyposis coli (APC) gene in adult T-cell leukemia/lymphoma. Leuk Res 2005; 29: 47–51
   PubMed Web of Science ®Google Scholar
• Salvatore P, Benvenuto G, Pero R, Lembo F, Bruni C B, Chiariotti L. Galectin-1 gene expression and methylation state in human T leukemia cell lines. Int J Oncol 2000; 17: 1015–1018
   PubMed Web of Science ®Google Scholar
• Hoshino K, Asou N, Okubo T, Suzushima H, Kiyokawa T, Kawano F, et al. The absence of the p15INK4B gene alterations in adult patients with precursor B-cell acute lymphoblastic leukaemia is a favourable prognostic factor. Br J Haematol 2002; 117: 531–540
   PubMed Web of Science ®Google Scholar
• Wong I H, Ng M H, Huang D P, Lee J C. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. Blood 2000; 95: 1942–1949
   PubMed Web of Science ®Google Scholar
• Chim C S, Tam C Y, Liang R, Kwong Y L. Methylation of p15 and p16 genes in adult acute leukemia: lack of prognostic significance. Cancer 2001; 91: 2222–2229
   PubMed Web of Science ®Google Scholar
• Chim C S, Wong A S, Kwong Y L. Epigenetic dysregulation of the Jak/STAT pathway by frequent aberrant methylation of SHP1 but not SOCS1 in acute leukaemias. Ann Hematol 2004; 83: 527–532
   PubMed Web of Science ®Google Scholar
• Roman-Gomez J, Jimenez-Velasco A, Agirre X, Cervantes F, Sanchez J, Garate J, et al. Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene 2005; 24: 7213–7223
   PubMed Web of Science ®Google Scholar
• Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002; 21: 5400–5413
   PubMed Web of Science ®Google Scholar
• Kaneda A, Tsukamoto T, Takamura-Enya T, Watanabe N, Kaminishi M, Sugimura T, et al. Frequent hypomethylation in multiple promoter CpG island is associated with global hypomethylation, but not with frequent promoter hypermethylation. Cancer Sci 2004; 95: 58–64
   PubMed Web of Science ®Google Scholar
• Pini J T, Franchina M, Taylor J ME, Kay P H. Evidence that general genomic hypomethylation and focal hypermethylation are two independent molecular events of non-Hodgkin's lymphoma. Oncol Res 2004; 14: 399–405
   PubMed Web of Science ®Google Scholar
• Frigola J, Sole X, Paz M F, Moreno V, Esteller M, Capella G, et al. Differential DNA hypermethylation and hypomethylation signatures in corectal cancer. Hum Mol Genet 2005; 14: 319–326
   PubMed Web of Science ®Google Scholar
• Yoshida M, Nosaka K, Yasunaga J, Nishikata I, Morishita K, Matsuoka M. Aberrant expression of the MEL1S gene identified in association with hypomethylation in adult T-cell leukemia cells. Blood 2004; 103: 2753–2760
   PubMed Web of Science ®Google Scholar
• Watt P M, Kumar R, Kees U R. Promoter demethylation accompanies reactivation of the HOX11 proto-oncogene in leukemia. Genes Chromosomes. Cancer 2000; 29: 371–377
   Web of Science ®Google Scholar
• Jones P A, Taylor S M. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980; 20: 85–93
   PubMed Web of Science ®Google Scholar
• Lubbert M. DNA methylation inhibitors in the treatment of leukemias, myelodisplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. Curr Top Microbiol Immunol 2000; 249: 135–164
   PubMed Web of Science ®Google Scholar
• Claus R, Lubbert M. Epigenetic targets in hematopoietic malignancies. Oncogene 2003; 22: 6489–6496
   PubMed Web of Science ®Google Scholar
• Szyf M, Pakneshan P, Rabbani S A. DNA demethylation and cancer: therapeutic implications. Cancer Lett 2004; 211: 133–143
   PubMed Web of Science ®Google Scholar
• Ruter B, Wijermans P W, Lubbert M. DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients with myelodysplasia and acute myeloid leukemia. Int J Hematol 2004; 80: 128–135
   PubMed Web of Science ®Google Scholar
• Avramis V I, Mecum R A, Nyce J, Steele D A, Holcenberg J S. Pharmacodynamic and DNA methylation studies of high-dose 1-β-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia. Cancer Chemother Pharmacol 1989; 24: 203–210
   PubMed Web of Science ®Google Scholar
• Youssef E M, Chen X Q, Higuchi E, Kondo Y, Garcia-Manero G, Lotan R, et al. Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers. Cancer Res 2004; 64: 2411–2417
   PubMed Web of Science ®Google Scholar
• Schmelz K, Sattler N, Wagner M, Lubbert M, Dorken B, Tamm I. Induction of gene expression by 5-aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms. Leukemia 2005; 19: 103–111
   PubMed Web of Science ®Google Scholar
• Shaker S, Bernstein M, Momparler L F, Momparler R L. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2′-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells. Leuk Res 2003; 27: 437–444
   PubMed Web of Science ®Google Scholar
• El Osta A, Kantharidis P, Zalcberg J R, Wolffe A P. Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation. Mol Cell Biol 2002; 22: 1844–1857
   PubMed Web of Science ®Google Scholar
• Lemaire M, Momparler L F, Farinha N J, Bernstein M, Momparler R L. Enhancement of antineoplastic action of 5-aza-2′-deoxycytidine by phenylbutyrate on L1210 leukemic cells. Leuk Lymphoma 2004; 45: 147–154
   PubMed Web of Science ®Google Scholar
• Park C H, Chang J Y, Hahm E R, Park S, Kim H K, Yang C H. Quercetin, a potent inhibitor against β-catenin/Tcf signaling in SW480 colon cancer cells. Biochem Biophys Res Commun 2005; 328: 227–234
   PubMed Web of Science ®Google Scholar
• Lepourcelet M, Chen Y N, France D S, Wang H, Crews P, Petersen F, et al. Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex. Cancer Cell 2004; 5: 91–102
   PubMed Web of Science ®Google Scholar
• Fenaux P. Inhibitors of DNA methylation: beyond myelodysplastic syndromes. Nat Clin Pract Oncol 2005; 2(Suppl 1)S36–S44
   PubMedGoogle Scholar